Biochemical assays and deep cyclic inhibition in cancer treatment
Drug Target Review's Taylor Mixides exclusively interviews Brett Hall, Chief…
Drug Target Review's Taylor Mixides exclusively interviews Brett Hall, Chief Scientific Officer at Immuneering, about his company’s aim to develop a universal-RAS therapy.